With many gene therapies in development for an increasing number of indications, their curative promise presents a unique competitive dynamic as they enter the market over the coming years. A one-time treatment with the potential to cure patients could create a “winner takes all” dynamic, whereby second and later entrants for the same indication would have significantly smaller patient populations, such as treatment-resistant or inappropriate patient segments.
100 days. 15 executive orders. Some bold healthcare policies.
In this CRA Insights, we assess the actions and impact of the second Trump Administration during the first 100 days that directly affect healthcare policy,...